SCHEMBL26449602

SCHEMBL26449602

Cc1cccc(CC[C@H](NC(=O)c2cnccn2)C(=O)N[C@@H](Cc2ccccc2)B2OC3C[C@@H]4C[C@@H](C4(C)C)[C@]3(C)O2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 17/20 0.81
PSMB1 P20618 4/20 0.61
PSMB2 P49721 3/20 0.61
PSMB11 A5LHX3 2/20 0.60
PSMA7 O14818 2/20 0.60
PSMA1 P25786 2/20 0.60
PSMA2 P25787 2/20 0.60
PSMA3 P25788 2/20 0.60
PSMA4 P25789 2/20 0.60
PSMB8 P28062 2/20 0.60
PSMB9 P28065 2/20 0.60
PSMA5 P28066 2/20 0.60
PSMB4 P28070 2/20 0.60
PSMB6 P28072 2/20 0.60
PSMB10 P40306 2/20 0.60
PSMB3 P49720 2/20 0.60
PSMA6 P60900 2/20 0.60
PSMA8 Q8TAA3 2/20 0.60
PSMB7 Q99436 2/20 0.60
PSMD11 O00231 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20905195 0.88 PSMB5 (0.87) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL21974554 0.88 PSMB5 (0.87) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL21652540 0.86 PSMB5 (0.87) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL26098947 0.85 PSMB5 (0.64) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL26098952 0.85 PSMB5 (0.64) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL26098955 0.85 PSMB5 (0.64) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL21532928 0.85 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL15590907 0.85 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL21652530 0.85 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMA7
SCHEMBL17059315 0.85 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024531-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-07-02 US disclosed
US-20230133165-A1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024531-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 PSMB5 15/4885PSMB1 6/4885PSMB2 3/4885
US-20230133165-A1 IMMUNOPROTEASOME INHIBITORS PSMC2, PSMB7, PSMB2 PSMB5 15/4885PSMB1 6/4885PSMB2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.